Aldeyra Therapeutics ALDX

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.21 (+3.34%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aldeyra Therapeutics (ALDX)
    Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $6.35

    • Market Cap

      $379.15 Million

    • Price-Earnings Ratio

      -8.47

    • Total Outstanding Shares

      59.71 Million Shares

    • Total Employees

      9

    • Dividend

      No dividend

    • IPO Date

      May 2, 2014

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      131 hartwell avenue, Lexington, MA, 02421

    • Homepage

      https://www.aldeyra.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities$-1.19 Million
    Net Cash Flow From Operating Activities, Continuing$-30.67 Million
    Net Cash Flow, Continuing$-75.21 Million
    Net Cash Flow From Investing Activities, Continuing$-43.35 Million
    Net Cash Flow$-75.21 Million
    Net Cash Flow From Financing Activities, Continuing$-1.19 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Basic Earnings Per Share$-0.75
    Nonoperating Income/Loss$4.84 Million
    Diluted Average Shares$59.54 Million
    Net Income/Loss$-44.80 Million
    Operating Income/Loss$-49.64 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-44.73 Million
    Comprehensive Income/Loss$-44.73 Million
    Other Comprehensive Income/Loss Attributable To Parent$66,540
    Other Comprehensive Income/Loss$66,540

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Equity$85.10 Million
    Wages$4.28 Million
    Current Liabilities$17.15 Million
    Liabilities$32.22 Million
    Other Non-current Assets$597,229
    Assets$117.32 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALDX from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.